Home › Compare › KDCXF vs ABBV
KDCXF yields 125.00% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 8
Combined, KDCXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KDCXF + ABBV for your $10,000?
Kudelski SA develops and delivers a range of digital security solutions for digital television and interactive applications in Switzerland, the United States, France, the Netherlands, and internationally. It operates through four segments: Digital TV, Cybersecurity, Internet of Things (IoT), and Public Access. The Digital TV segment offers integrated solutions, including open conditional access solutions, which allow TV operators and content providers to operate various value-added pay-TV services on a secure platform, and middleware software solutions for set-top boxes and other consumer devices; and intellectual property consulting services. The Cybersecurity segment provides cybersecurity solutions to enterprises and public sector institutions, which include consulting, technology and resale services, managed security and custom developed proprietary products, and threat intelligence solutions that help organizations to build and run security programs. The IoT segment offers device security through identity authentication and firmware protection; data security to ensure the confidentiality, integrity, and authenticity of sensitive data; and access management and active security protections to enable secure processing, local decision making, and threat detection and response. The Public Access segment provides access control systems and ticketing services for ski lifts, car parks, stadiums, concert halls, and other events. The company also offers watermarking solutions; smartcards and digital TV sales and support services; research and development services; finance services; and research and development digital broadcasting solutions, as well as operates a travel agency. Kudelski SA was founded in 1951 and is headquartered in Cheseaux-sur-Lausanne, Switzerland.
Full KDCXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.